1. Home
  2. GKOS vs CHX Comparison

GKOS vs CHX Comparison

Compare GKOS & CHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • CHX
  • Stock Information
  • Founded
  • GKOS 1998
  • CHX 1882
  • Country
  • GKOS United States
  • CHX United States
  • Employees
  • GKOS N/A
  • CHX N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • CHX Industrial Machinery/Components
  • Sector
  • GKOS Health Care
  • CHX Industrials
  • Exchange
  • GKOS Nasdaq
  • CHX Nasdaq
  • Market Cap
  • GKOS 5.1B
  • CHX 4.9B
  • IPO Year
  • GKOS 2015
  • CHX N/A
  • Fundamental
  • Price
  • GKOS $94.31
  • CHX $24.07
  • Analyst Decision
  • GKOS Strong Buy
  • CHX Strong Buy
  • Analyst Count
  • GKOS 13
  • CHX 3
  • Target Price
  • GKOS $135.15
  • CHX $37.67
  • AVG Volume (30 Days)
  • GKOS 914.5K
  • CHX 3.0M
  • Earning Date
  • GKOS 04-30-2025
  • CHX 07-23-2025
  • Dividend Yield
  • GKOS N/A
  • CHX 1.58%
  • EPS Growth
  • GKOS N/A
  • CHX N/A
  • EPS
  • GKOS N/A
  • CHX 1.51
  • Revenue
  • GKOS $404,523,000.00
  • CHX $3,576,306,000.00
  • Revenue This Year
  • GKOS $27.89
  • CHX $0.17
  • Revenue Next Year
  • GKOS $27.57
  • CHX $3.65
  • P/E Ratio
  • GKOS N/A
  • CHX $15.94
  • Revenue Growth
  • GKOS 23.92
  • CHX N/A
  • 52 Week Low
  • GKOS $77.10
  • CHX $21.92
  • 52 Week High
  • GKOS $163.71
  • CHX $35.94
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 50.08
  • CHX 38.61
  • Support Level
  • GKOS $93.52
  • CHX $24.00
  • Resistance Level
  • GKOS $101.57
  • CHX $25.05
  • Average True Range (ATR)
  • GKOS 3.33
  • CHX 0.55
  • MACD
  • GKOS 0.40
  • CHX -0.06
  • Stochastic Oscillator
  • GKOS 42.24
  • CHX 4.70

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About CHX ChampionX Corporation

ChampionX provides chemical solutions and equipment for onshore and offshore oil and gas production. Its engineering expertise spans the well lifecycle, but the firm maintains a particular focus on the production phase. Key offerings include artificial lift services and drilling technologies, specializing in polycrystalline diamond cutter inserts. ChampionX was formed after Apergy acquired its chemical technologies business from Ecolab in 2020.

Share on Social Networks: